$3.77
1.89% today
Nasdaq, Feb 05, 04:23 pm CET
ISIN
US14179K1016
Symbol
CRGX
Sector
Industry

CARGO Therapeutics Stock price

$3.70
-10.28 73.53% 1M
-11.02 74.86% 6M
-10.72 74.34% YTD
-18.35 83.22% 1Y
-11.30 75.33% 3Y
-11.30 75.33% 5Y
-11.30 75.33% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.05 1.37%
ISIN
US14179K1016
Symbol
CRGX
Sector
Industry

Key metrics

Market capitalization $170.30m
Enterprise Value $-205.97m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.47
P/B ratio (TTM) P/B ratio 0.42
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-172.19m
Free Cash Flow (TTM) Free Cash Flow $-140.27m
Cash position $404.85m
EPS (TTM) EPS $-3.55
P/E forward negative
Short interest 18.16%
Show more

Is CARGO Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

CARGO Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a CARGO Therapeutics forecast:

1x Buy
10%
8x Hold
80%
1x Sell
10%

Analyst Opinions

10 Analysts have issued a CARGO Therapeutics forecast:

Buy
10%
Hold
80%
Sell
10%

Financial data from CARGO Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 6.79 6.79
-
-
-6.79 -6.79
-
-
- Selling and Administrative Expenses 29 29
-
-
- Research and Development Expense 130 130
-
-
-165 -165
-
-
- Depreciation and Amortization 6.79 6.79
-
-
EBIT (Operating Income) EBIT -172 -172
-
-
Net Profit -154 -154
-
-

In millions USD.

Don't miss a Thing! We will send you all news about CARGO Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CARGO Therapeutics Stock News

Neutral
PRNewsWire
6 days ago
LOS ANGELES , Jan. 30, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ: CRGX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Business Wire
7 days ago
LOS ANGELES--(BUSINESS WIRE)--CARGO Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CRGX.
Neutral
GlobeNewsWire
7 days ago
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel) 1 ; Company believes results do not support a competitive benefit-risk profile for patients. CARGO to implement a workforce reduction of approximately 50%.
More CARGO Therapeutics News

Company Profile

Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Mateo, CA.

Head office United States
CEO Gina Chapman
Founded 2019
Website cargo-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today